pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions
暂无分享,去创建一个
Ismael Zamora | Per Artursson | Sibylle Neuhoff | P. Artursson | I. Zamora | A. Ungell | S. Neuhoff | Anna-Lena Ungell
[1] M Zschiesche,et al. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.
[2] I. D. de Lannoy,et al. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. , 1992, Biochemical and biophysical research communications.
[3] Yoshinori Morita,et al. MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.
[4] K. Luthman,et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. , 1998, Journal of medicinal chemistry.
[5] Roger L. Black,et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .
[6] T. Márián,et al. Intracellular pH does not affect drug extrusion by P-glycoprotein. , 1996, Journal of photochemistry and photobiology. B, Biology.
[7] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[8] D. Clarke,et al. The “LSGGQ” Motif in Each Nucleotide-binding Domain of Human P-glycoprotein Is Adjacent to the Opposing Walker A Sequence* , 2002, The Journal of Biological Chemistry.
[9] G. Klebe,et al. Transport of Peptidomimetic Thrombin Inhibitors with a 3-Amidino-Phenylalanine Structure: Permeability and Efflux Mechanism in Monolayers of a Human Intestinal Cell Line (Caco-2) , 2001, Pharmaceutical Research.
[10] R. Pownall,et al. The absorption of β‐adrenoceptor antagonists in rat in‐situ small intestine; the effect of lipophilicity , 1985, The Journal of pharmacy and pharmacology.
[11] M. Boisset,et al. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[12] B. H. Stewart,et al. Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion , 2000, Journal of clinical pharmacology.
[13] M. Kataoka,et al. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] J. Schellens,et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. , 1999, Pharmacological research.
[15] W. L. Chiou,et al. An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol. , 2001, Clinical pharmacology and therapeutics.
[16] L. A. Christensen,et al. pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry device , 1989, Alimentary pharmacology & therapeutics.
[17] A. Tsuji,et al. GI absorption of beta-lactam antibiotics II: deviation from pH--partition hypothesis in penicillin absorption through in situ and in vitro lipoidal barriers. , 1978, Journal of pharmaceutical sciences.
[18] K. Luthman,et al. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. , 1999, The Journal of pharmacology and experimental therapeutics.
[19] J. Belli,et al. Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[21] W. Kirch,et al. Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.
[22] P. Artursson,et al. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[23] A. Seelig,et al. Real-time monitoring of P-glycoprotein activation in living cells. , 2002, Biochemistry.
[24] G R Wilkinson,et al. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.
[25] N. Holford,et al. Pharmacokinetics of quinidine and three of its metabolites in man , 1984, Journal of Pharmacokinetics and Biopharmaceutics.
[26] D. Clarke,et al. Location of the Rhodamine-binding Site in the Human Multidrug Resistance P-glycoprotein* , 2002, The Journal of Biological Chemistry.
[27] C. Joyce. Drug Compendium , 1970, Nature.
[28] D. Keppler,et al. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.
[29] Thomas J. Raub,et al. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. , 1994, Journal of pharmaceutical sciences.
[30] J. Nezu,et al. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. , 1999, The Journal of pharmacology and experimental therapeutics.
[31] B. Brodie,et al. The gastric secretion of drugs: a pH partition hypothesis. , 1957, The Journal of pharmacology and experimental therapeutics.
[32] R. Oertel,et al. Interaction of talinolol and sulfasalazine in the human gastrointestinal tract , 1992, European Journal of Clinical Pharmacology.
[33] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] B. Hirst,et al. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. , 1991, British Journal of Cancer.
[35] G. McEwan,et al. The effect of E. coli STa enterotoxin on the absorption of weakly dissociable drugs from rat proximal jejunum in vivo , 1990, British journal of pharmacology.
[36] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[37] B. Faller,et al. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. , 2001, Journal of medicinal chemistry.
[38] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .
[39] Thomas J. Raub,et al. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.
[40] N. Ellison. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th Edition , 2002 .